Get the Stockscreener App
0.00
100.00%
-5.11
After Hours:
5.10
5.10
+
Eliem Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its main drug candidate is ETX-155 for major depressive disorder (MDD) and focal onset seizures (FOS).
See More
Previous Close:
$5.11
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$342.68M
Revenue:
-
Net Income/Loss:
$-64.20M
P/E Ratio:
0.00
EPS:
-2.15
Net Cash Flow:
$57,000
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$11.55
Eliem Therapeutics Inc Stock (ELYM) Company Profile
Name
Eliem Therapeutics Inc
Sector
Industry
Phone
877-354-3689
Address
2801 CENTERVILLE ROAD 1ST FLOOR, WILMINGTON
Compare ELYM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELYM
Eliem Therapeutics Inc
|
0.00 | 342.68M | 0 | -64.20M | 57,000 | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.97 | 121.03B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
690.36 | 75.47B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.45 | 39.28B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.06 | 35.35B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.27 | 27.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eliem Therapeutics Inc Stock (ELYM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
Eliem Therapeutics Inc Stock (ELYM) Latest News
Eliem Therapeutics, Inc. (NASDAQ:ELYM) Shares Bought by JPMorgan Chase & Co. - Defense World
Barclays PLC Acquires 36,316 Shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) - Defense World
Jane Street Group LLC Purchases New Position in Eliem Therapeutics, Inc. (NASDAQ:ELYM) - Defense World
Eliem Therapeutics Enters into Exclusive Licensing Agreement with Beijing Mabworks Biotech - Defense World
State Street Corp Has $1.60 Million Holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM) - Defense World
Eliem Therapeutics stock hits 52-week low at $1.86 amid market shifts - Investing.com Australia
Eliem Therapeutics stock hits 52-week low at $1.86 amid market shifts By Investing.com - Investing.com South Africa
Financial Analysis: TransCode Therapeutics (NASDAQ:RNAZ) & Eliem Therapeutics (NASDAQ:ELYM) - Defense World
Eliem Therapeutics, Inc. (NASDAQ:ELYM) Holdings Boosted by Charles Schwab Investment Management Inc. - Defense World
The Manufacturers Life Insurance Company Acquires Shares of 49,524 Eliem Therapeutics, Inc. (NASDAQ:ELYM) - Defense World
590,946 Shares in Eliem Therapeutics, Inc. (NASDAQ:ELYM) Acquired by Point72 Asset Management L.P. - MarketBeat
Janus Henderson Group PLC Has $18.30 Million Stake in Eliem Therapeutics, Inc. (NASDAQ:ELYM) - MarketBeat
Samsara BioCapital LLC Has $13.28 Million Stake in Eliem Therapeutics, Inc. (NASDAQ:ELYM) - MarketBeat
Parkman Healthcare Partners LLC Takes Position in Eliem Therapeutics, Inc. (NASDAQ:ELYM) - MarketBeat
Ally Bridge Group NY LLC Purchases 729,292 Shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) - MarketBeat
Great Point Partners LLC Buys New Stake in Eliem Therapeutics, Inc. (NASDAQ:ELYM) - MarketBeat
Eliem Therapeutics To Acquire Tenet Medicines - Contract Pharma
How To Trade (CLYM) - Stock Traders Daily
Climb Bio to present kidney disease treatment study - Investing.com India
Climb Bio to present kidney disease treatment study By Investing.com - Investing.com UK
Eliem Therapeutics Inc [ELYM] Shares Fall -0.97 % on Wednesday - Knox Daily
Eliem Therapeutics mounts corporate rebrand after pipeline overhaul, mass layoffs - FiercePharma
Eliem Therapeutics rebrands to Climb Bio, shifts focus to immune diseases - Investing.com
Eliem Therapeutics Changes Name to Climb Bio - Yahoo Finance
Eliem Therapeutics to change corporate name to Climb Bio - TipRanks
Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc. - The Manila Times
Healthy Upside Potential: Eliem Therapeutics Inc (ELYM) - SETE News
Monitoring Eliem Therapeutics Inc (ELYM) after recent insider movements - Knox Daily
Eliem Therapeutics Inc (ELYM) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Ratio Analysis: Unpacking Eliem Therapeutics Inc (ELYM)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Eliem Therapeutics, Inc. (NASDAQ:ELYM) Stock Position Decreased by Driehaus Capital Management LLC - MarketBeat
Selling Eliem Therapeutics Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - Simply Wall St
Private equity firms who have a significant stake must be disappointed along with institutions after Eliem Therapeutics, Inc.'s (NASDAQ:ELYM) market cap dropped by US$231m - Yahoo Finance
Eliem Therapeutics Inc (ELYM) can make a big difference with a little luck - SETE News
Eliem Therapeutics Inc (ELYM) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Affinity Asset Advisors LLC Takes $11.88 Million Position in Eliem Therapeutics, Inc. (NASDAQ:ELYM) - MarketBeat
Trading (ELYM) With Integrated Risk Controls - Stock Traders Daily
500,000 Shares in Eliem Therapeutics, Inc. (NASDAQ:ELYM) Acquired by Ally Bridge Group NY LLC - MarketBeat
Eliem Therapeutics: Recent Strategic Pipeline Restructuring (NASDAQ:ELYM) - Seeking Alpha
Closing Figures: Eliem Therapeutics Inc (ELYM)’s Positive Finish at 8.43, Up 1.81 - The Dwinnex
Eliem Therapeutics Inc (ELYM)’s stock price in review: A technical analysis - US Post News
Eliem therapeutics executive sells over $9,000 in company stock By Investing.com - Investing.com Australia
Eliem therapeutics executive sells over $9,000 in company stock - Investing.com
(ELYM) Trading Signals - Stock Traders Daily
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit - GlobeNewswire
Eliem Therapeutics (NASDAQ:ELYM) Trading Up 4.6% - MarketBeat
Eliem Therapeutics Inc Stock (ELYM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
1.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):